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A B S T R A C T
Purpose: Development of ex vivo model to study pathogenesis, inﬂammation and treatment modalities for
pterygium.
Methods: Pterygium obtained from surgery was cultivated (3 months). Gravitational attachment method using
viscoelastic facilitated adherence of graft and outgrowing cells. Medium contained serum as the only growth
supplement with no use of scaﬀolds. Surface proﬁling of the multi-layered cells for hematopoietic- and
mesenchymal stem cell markers was performed. Examination of cells by immunohistochemistry using
pluripotency, oxidative stress, stemness, migration and proliferation, epithelial and secretory markers was
performed. The eﬀect of anti-proliferative agent Mitomycin C upon secretion of pro-inﬂammatory cytokines IL-6
and IL-8 was assessed.
Results: Cells showed high expression of migration- (CXCR4), secretory- (MUC1, MUC4) and oxidative damage-
(8-OHdG) markers, and low expression of hypoxia- (HIF-1α) and proliferation- (Ki-67) markers. Moderate and
low expression of the pluripotency markers (Vimentin and ΔNp63) was present, respectively, while the putative
markers of stemness (Sox2, Oct4, ABCG-2) and epithelial cell markers- (CK19, CK8-18) were weak. The surface
marker proﬁle of the outgrowing cells revealed high expression of the hematopoietic marker CD47,
mesenchymal markers CD90 and CD73, minor or less positivity for the hematopoietic marker CD34,
mesenchymal marker CD105, progenitor marker CD117 and attachment protein markers while low levels of
IL-6 and IL-8 secretion ex vivo, were inhibited upon Mitomycin C treatment.
Conclusion: Ex vivo tissue engineered pterygium consists of a mixture of cells of diﬀerent lineage origin, suitable
for use as a disease model for studying pathogenesis ex vivo, while opening possibilities for new treatment and
prevention modalities.
1. Introduction
Pterygium is a common ocular surface disorder characterized by an
active wing-shaped overgrowth of epithelial and ﬁbrovascular tissue
growing from the conjunctiva towards the limbus and onto the cornea,
thus giving cosmetic alterations to the ocular surface and in advanced
cases impairing vision [1–4]. It consists of a head which falls onto the
anterior cornea, a neck which covers the superﬁcial limbus, and a body
which overlies the sclera. The ﬁrst sign of pterygium is formation of a
cap which appears as halo in front of the head and goes deep into the
epithelium without respecting the limbal epithelium stem cell border
[5]. It is not fully known whether the stem cell deﬁciency alone or other
factors drive the centripetal migration of the pterygium cells onto the
cornea, or how sclera support may play a role in the process.
The pathogenesis of pterygium remains uncertain, although it is
thought to be mainly caused by ultraviolet (UV) radiation. A wide range
of alternative pathogenic factors have been proposed, including viral
infections, epigenetic aberrations, epithelial-mesenchymal transition,
immunologic and anti-apoptotic mechanisms, angiogenic and lymphan-
giogenic stimulation, deregulation of extracellular matrix (ECM) mod-
ulators and growth factors, inﬂammation cascades, recruitment of
bone-marrow-derived stem- and progenitor cells, and modiﬁcations in
the cholesterol metabolism. Most of these factors are rather related to
the development and maintenance of the disease than to its origin [6].
In the present study, cells were adherently cultivated and grown out
of the pterygium using gravitational force from viscoelastic material for
more than three months or until they formed multi-layered structures.
Surface marker proﬁling using hematopoietic- and mesenchymal stem
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cell (HSC and MSC) markers to determine the possible phenotype and
origin of these cells was also used. Furthermore, full characterization of
markers for pluripotency and stemness: Vimentin (Vim), tumour/
transformation-related protein 63 (p63/TP63), Sex Determining
Region Y-related HMG-box (Sox2), Octamer-binding transcription
factor 4 (Oct4), and ATP-binding cassette sub-family G member 2
(ABCG-2), oxidative stress: 8-hydroxy-2' −deoxyguanosine (8-OHdG)
and hypoxia-inducible factor 1 alpha (HIF-1α), migration and
proliferation:C-X-C chemokine receptor type 4 (CXCR4) and (Ki-67/
MKI67), epithelial: Cytokeratin (CK19 and 8–18) and secretory mar-
kers: Mucin (MUC1 and MUC4) was done.
Inﬂammatory processes in the pterygium can cause reactive wound
formation, which may induce dysregulated and inappropriate tissue
remodelling, ﬁbrotic proliferation, enhanced vascularization and de-
position of ECM, leading to formation of hypertrophic scarring and
recurrence. Inﬂammation can induce the angiogenic pathways, which
can result in neovascularization and contribute to further pterygium
growth. Mitomycin C (MMC), an anti-mitotic agent often used in
recurrent pterygium ablation surgery can induce apoptosis of kerato-
cytes and myoﬁbroblasts [6]. Herein, the eﬀect MMC has upon the
secretion of pro-inﬂammatory cytokines, interleukin 6 (IL-6) and IL-8
was checked after repeated pterygium graft cultivation, thus resembling
closely its application in vivo for recurrent cases.
2. Materials and methods
2.1. Pterygium harvesting and cultivation
All tissue collection complied with the Guidelines of the Helsinki
Declaration and was obtained from surgery following a patient signed
consent. The tissue harvesting was approved by the Local Committee
for Medical Research Ethics at University of Oslo. The removed graft
was then cultivated in 24-well cell culture plates using Dulbecco-
modiﬁed Eagle’s medium (DMEM) with 4.5 g glucose/L supplemented,
10% fetal bovine serum (FBS) and 200 mM/mL L-glutamine (Sigma-
Aldrich, Germany), as well as 1% antibiotic/antimycotic solution (PAA,
Pasching, Austria). Before cultivation, viscoelastic (ProVisc, Alcon, Fort
Worth, TX, USA) [7] was added on top of the explant to allow ﬂattening
and adherence of the tissue onto the surface of the well. Medium was
changed every other day and the tissues were cultivated for more than
three months or until they formed multi-layered cells which could be
lifted easily from the cell culture plate by Colibri forceps before ﬁxation
and further analysis.
2.2. Cell viability assay
Cell viability was determined using Annexin V-Fluorescein isothio-
cyanate (FITC)/Propidium Iodide (PI) assay (MBL International,
Woburn, MA, USA) and trypan blue exclusion test (Sigma Aldrich,
MO, USA). For both assays, the cells were collected by trypsinization in
culturing media, then centrifuged and resuspended in Binding Buﬀer
for the Annexin V-FITC/PI assay. Furthermore, they were stained with
Annexin V-FITC, PI, and Annexin V-FITC/PI and analysed by Flowing
Software 2.5 (PerttuTerho, Turku Centre for Biotechnology, University
of Turku, Finland). 50 μL cell suspension was mixed with equal parts of
trypan blue solution and cells were counted in a Hemocytometer
(Burker chamber).
2.3. Immunophenotyping of cells
The immunophenotype of the long-term multi-layered cultures of
pterygium containing outgrowing cells was determined by ﬂow cyto-
metry. FITC-, R-phycoerythrin (PE)- and allophycocyanin (APC)- con-
Fig. 1. Cell morphology, viability and phenotyping of the cultivated pterygium. Fibroblastic cells (Aa), pterygium epithelial cells (Ab) and graft with outgrowing cells forming 3D layered
structure (Ac) (Magniﬁcation: 10×, (*) 20× and (**) 40×). Cellular viability of the 3D outgrowing cells from the pterygium using Annexin V-FITC/PI assay and Trypan blue exclusion
test (B). Cell surface markers phenotyping of the 3D outgrowing cells by FACS analysis; a plot of the percent positive cells versus diﬀerent markers is shown as mean ± SD (C).
Table 1
Immunophenotyping of the multi-layered outgrowing pterygium cells. Expression of
diﬀerent surface markers shown as percent (%).
Multi-layered outgrowing pterygium cells
HSC markers CD34 10.8 ± 12.7%
CD47 79.1 ± 17%
Progenitor marker CD117/c-kit 3.3. ± 3.2%
MSC markers CD90 87.2 ± 9.5%
CD73 76.4 ± 11%
CD105 1.3 ± 1.4%
ECM attachment proteins markers CD146/MCAM 2.6 ± 4.7%
CD166/ALCAM 48.1 ± 18.1%
CD44/H-CAM 41.5 ± 12.3%
CD112/Nectin-2 4.1 ± 4%
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jugated antibodies were used to measure the expression of CD34, CD44,
CD90/Thy-1, CD73, CD105 and CD166/ALCAM (all from Biolegend,
San Diego, CA, USA); CD47, CD117/c-kit, CD146/MCAM, CD112 (all
from R&D Systems, Minneapolis, MN, USA) (for further details refer to
S1Table). Samples were measured by FACS Calibur ﬂow cytometer (BD
Biosciences Immunocytometry Systems) and data were analysed by
Flowing Software 2.5 (PerttuTerho, Turku Centre for Biotechnology,
University of Turku, Finland).
2.4. Immunoﬂuorescent staining
Pterygium obtained right after surgery and that cultivated as long-
term multi-layered cultures were collected and ﬁxed in 4% parafor-
maldehyde at room temperature, later dehydrated in ascending alcohol
series and embedded in paraﬃn; 3–4 μm thick tissue sections were
prepared using a rotary microtome, then mounted onto histological
slides. After heat-induced antigen retrieval and blocking, immunoﬂuor-
escent labelling was performed. The samples were characterized for
markers of pluripotency and stemness (Vim, ΔNp63, Sox2, Oct4, ABCG-
2,), oxidative stress (8-OHdG, HIF-1α), migration and proliferation-
(CXCR4 and Ki-67), epithelial- (CK19 and 8–18) and secretory markers
(MUC1 and MUC4) (S2 Table summarizes the primary antibodies and
dilutions used for immunoﬂuorescent staining). Nuclear staining was
performed using 4′, 6-diamidino-2-phenylindole (DAPI). Fluorescent
images were taken by a ZEISS Axio Observer.Z1 (ZEISS, Oberkochen,
Germany) microscope. The quantiﬁcation of positive cells was carried
out using standard ImageJ software by three independent individuals.
The number of positive cells on the full ﬁeld of view was taken into
account with the help of nuclear (DAPI) staining. Multiple pictures
were taken of each sample and the results averaged out as mean ±
standard deviation (SD).
2.5. Secretion of inﬂammatory cytokines by ELISA
High glucose-containing DMEM medium with 5% FBS was applied
to the multi-layered outgrowing cells and the supernatants were
collected after 24 h. In addition, treatment of the cells with 0.5 mg/
mL MMC (Kyowa, Takeda Belgium-Brussels) was applied for 5 min and
exchanged by fresh medium for another 15 min prior to the supernatant
collection, thus resembling the clinical use of MMC in surgery. Limbal
epithelial stem cell (LESC) cultures cultivated in high glucose-contain-
ing medium with 10% FBS were also used as a control. The secreted
cytokines, IL-6 and IL-8, were analysed by a commercial ELISA kit
(R & D, Germany) according to the manufacturer's protocol. Three
independent experiments were performed on outgrowing cells from
four diﬀerent pterygium donors.
Fig. 2. Pterygium tissue and 3D outgrowing cells stained for pluripotency markers. Pterygium tissue-containing cultures (A, C), and outgrowing cells forming 3D structures (B, D) were
stained for Vim and ΔNp63, respectively (Magniﬁcation: 40×). White bar represents data from pterygium tissue, while the black bar shows results from independently grown 3D
outgrowing cells. Data are expressed as mean ± SD.
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2.6. Statistical analysis
Each experiment was performed at least three times and each
sample was tested in triplicates. Data are expressed as mean ± stan-
dard deviation (SD). Statistically signiﬁcant diﬀerences were deter-
mined by student-t-tests, a p-value≤ 0.05 was regarded signiﬁcant.
3. Results
Pterygium morphology depends on two types of cells: ﬁbroblastic
which are long-shaped (Fig. 1Aa), and squamous epithelial cells tightly
packed together (Fig. 1Ab). After long term cultivation, pterygium
formed spontaneous multi-layered structure that was easily tangible
and removable from the plate for further analysis (Fig. 1Ac). The
viability of the outgrowing cells tested by the Annexin V-FITC/PI assay
and Trypan blue method was (98.6 ± 1.7% and 82.6 ± 6.9%),
respectively (Fig. 1B). The expression of hematopoietic cell surface
markers CD34 and CD47 was (10.8 ± 12.7%and 79.1 ± 17%),
respectively. CD117/c-kit, a progenitor cell marker was low
(3.3 ± 3.2%), while a very high expression of the MSC markers
CD90 (87.2 ± 9.5%) and CD73 (76.4 ± 11%) were measured, in
contrast to the MSC marker CD105 which was (1.3 ± 1.4%). The
Fig. 3. Pterygium tissue and 3D outgrowing cells stained for markers of stemness. Pterygium tissue-containing cultures (A, C and E), and outgrowing cells forming 3D structures (B, D and
F) were stained for Sox2, Oct4 and ABCG-2, respectively (Magniﬁcation: 40×). White bar represents data from pterygium tissue, while the black bar shows results from independently
grown 3D outgrowing cells. Data are expressed as mean ± SD.
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expression of ECM attachment proteins, which is important for the
maintenance of the cellular growth were tested next: CD146/MCAM
(2.6 ± 4.7%), CD166/ALCAM (48.1 ± 18.1%), CD112/Nectin-2
(4.1 ± 4%) and CD44/homing-associated cell adhesion molecule (H-
CAM) (41.5 ± 12.3%) (Fig. 1C). The expression of surface markers (%)
is summarised in Table 1.
Immunoﬂuorescent staining of a wide range of markers involved in
the diﬀerent pathways were examined in the pterygium grafts obtained
directly from surgery and compared to those from long-term cultivated
3D outgrowths from the pterygia. The expression of pluripotency
markers (Vim and ΔNp63) was (26.5 ± 3.5% and 13.9 ± 0.9%),
respectively, in the pterygium graft tissue only, and (43.7 ± 4% and
12.3 ± 1.5%), respectively, in the multi-layered outgrowing cells
(Fig. 2), while other stemness markers (Sox2, Oct4 and ABCG-2)
showed positivity in (22.2 ± 0.9%, 34.2 ± 1.6% and 25 ± 5%) of
the cells in the pterygium graft itself, respectively, and (15.3 ± 0.6%,
39.2 ± 2.5% and 32.7 ± 6.6), respectively, within the multi-layered
outgrowing cells (Fig. 3). Oxidative stress markers (8-OHdG and HIF-
1α) were determined in the pterygium graft tissue (42.4 ± 3% and
13.8 ± 2.3%), respectively and in the multi-layered outgrowing cells
(62.3 ± 8.6% and 26.6 ± 4.8%), respectively (Fig. 4). The expression
of migration and proliferation markers − CXCR4 and Ki-67, was
(27.2 ± 4.5% and 5.1 ± 0.4%), respectively, in the pterygium graft
tissue, and (67.3 ± 4.7% and 1.2 ± 0.3%), respectively, in the multi-
layered outgrowing cells (Fig. 5). The epithelial cell markers expression
(CK19 and CK8-18) was (0% and 24.3 ± 6.5%) for the pterygium graft
tissue, and (11.9 ± 3.7% and 0%), respectively, for the multi-layered
outgrowing cells (Fig. 6), while that for the secretory markers (MUC1
and MUC4) was (13.1 ± 4.3% and32.2 ± 3.3%), respectively, for the
pterygium graft tissue, and (63.7 ± 5.7% and 55.3 ± 5%), respec-
tively, for the multi-layered outgrowing cells (Fig. 7). Expression of all
markers (%) is summarised in Table 2.
The multi-layered outgrowing cells from the pterygium biopsies
secreted moderate and low levels of the pro-inﬂammatory cytokine IL-
6and IL-8, respectively, which levels were signiﬁcantly decreased upon
treatment with the anti-proliferative agent MMC, in contrast to the level
secreted by LESCs (control) for IL-6 (p < 0.05). The IL-8 secretion
upon MMC treatment showed no signiﬁcant change, although it was
lower than that secreted by LESCs (Fig. 8A and B). Both, the
inﬂammatory cytokines’ release and the treatment by MMC have
clinical relevance in case of recurrent pterygia.
4. Discussion
Being a benign process of uncontrolled cell proliferation, pterygium
is a common ocular surface disorder which can vary from locally
invasive, mild dysplasia to carcinoma in situ, characterized by prolif-
eration, inﬂammation, ﬁbrosis, angiogenesis and ECM breakdown
Fig. 4. Pterygium tissue and 3D outgrowing cells stained for oxidative stress markers. Pterygium tissue-containing cultures (A, C), and outgrowing cells forming 3D structures (B, D) were
stained for 8-OHdG and HIF-1α, respectively (Magniﬁcation: 40×). White bar represents data from pterygium tissue, while the black bar shows results from independently grown 3D
outgrowing cells. Data are expressed as mean ± SD.
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[8–10]. The pathogenesis of pterygia is partly unknown, but might be
due to an alteration of the normal stationary limbal epithelial basal cells
giving rise to a zone of motile daughter cells − pterygium cells, which
leave the limbal region and migrate as a group centripetally along the
corneal basement membrane dissolving the Bowman’s layer. Matrix
metalloproteinases (MMP) take a role in the process of squamous
metaplasia and goblet cells' hyperplasia [11–14].
Pterygium as a structure consists of a mixture of epithelial and
ﬁbroblastic cells, proliferation of which closely determines its recur-
rence and severity [6]. The stratiﬁed outgrowing cell model for
pterygium expansion ex vivo shown here has the advantage of giving
immediate adherence of the graft to the cell culture plate (e.g. using
viscoelastic material), therefore, providing both cell types an equal
chance to expand, without the use of any growth factors. The out-
growing cells expressed CK8-18 −a typical epithelial cell marker also
expressed by other human corneal cells such as epithelial and endothe-
lial cells [15,16], as well as the LESC marker CK19 [17,18].
Cellular homeostasis or the balance between proliferation and
apoptosis can be disrupted in pterygia [19]. The disorder shares many
similarities with cancer, in terms of cell proliferation, invasion and
recurrence after resection. The proliferation marker Ki-67 has been
found to be overexpressed in the epithelial cell layer of pterygium
rather than in the stromal ﬁbroblasts, in particular, the head and the
body parts compared to the healthy conjunctiva. Accordingly, corneal
invasion by the pterygium might be associated with proliferation of the
epithelium, although it is clear that ﬁbroblasts play important role in
epithelial–mesenchymal interactions [6,20–22]. Ki-67 has also been
expressed in conjunctival and eyelid tumours [23], the positivity of
which was low in the pterygium graft containing cultures, which was
additionally ﬁve times less expressed in the multi-layered outgrowing
tissue. The SDF-1/CXCR4 signalling pathway has been described in
developmental processes and adult angiogenesis to have a role in
vascular endothelial cell migration and proliferation [24]. LESCs
themselves possess migratory capacity or positivity for CXCR4 [17],
while this marker is expressed by vascular endothelial cells in prolif-
erative diabetic retinopathy membranes as well [25]. The pterygium
graft-containing cultures showed 2.5 times less positivity for CXCR4
compared to multi-layered outgrowing cell cultures. Vimentin, a crucial
cytoskeletal mediator for the repair of cellular function during wound-
healing from lens epithelial cells [26] and in LESCs cultivated in long-
term cultures [18], was found highly expressed by the pterygium-graft
containing and the stratiﬁed outgrowing cells. Similarly, ΔNp63 was
expressed at a steady and similar extent in both cell cultures, the
protein being known for its role in activation or inhibition of apoptosis
in a cell- and tissue-type speciﬁc manner. In fact, ΔNp63α is the most
present isoform in the central corneal epithelium which seems to be lost
during apoptotic cell death [27]. Furthermore, ΔNp63 is important in
the regulation of LESC proliferation, and its expression in the limbal
Fig. 5. Pterygium tissue and 3D outgrowing cells stained for migration and proliferation markers. Pterygium tissue-containing cultures (A, C), and outgrowing cells forming 3D structures
(B, D) were stained for CXCR4 and Ki-67, respectively (Magniﬁcation: 40×). White bar represents data from pterygium tissue, while the black bar shows results from independently
grown 3D outgrowing cells. Data are expressed as mean ± SD.
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epithelium plays a role in the homeostasis of corneo-limbal epithelium
in rabbit limbal epithelial cells [28].
UV-B radiation is considered to be the main factor responsible for
pterygium formation due to its capacity to cause oxidative stress, which
plays an important role in its recurrence as well. Oxidative stress can
induce growth factor production, angiogenesis, chronic inﬂammation
and collagenolysis. When sunlight triggers pterygium inception, the
proliferating ﬁbroblasts generate reactive oxygen species that further
sustain inﬂammation [5]. UV light can activate epithelial cells close to
the limbus to produce cytokines such as IL-6 and IL-8, and enhance
inﬂammation, proliferation, angiogenesis and anti-apoptosis. IL-8 is
secreted from activated monocytes, ﬁbroblasts, endothelial and epithe-
lial cells, while IL-6 is synthesized by ﬁbroblasts, endothelial cells and
keratinocytes in response to cytokines as well as TNF-α and IL-1. In
pterygia, IL-6 and IL-8 are believed to promote angiogenesis within the
epithelium, or to stimulate mitosis in these cells and in ﬁbroblasts
together with VEGF, ﬁbroblast growth factor-2 (FGF-2), epidermal
growth factor (EGF), and platelet-derived growth factor (PDGF). An
abundant immunopositivity for IL-6 and IL-8 has indeed been found in
pterygium epithelial cells [4,29], while in the 3D pterygium outgrowing
cells, only IL-6 appeared to be highly expressed. Likely, the expression
of these cytokines is closely related to the factors associated with the
niche where pterygia sit in vivo, where they are closely related to the
neighbouring limbus and its abundant vasculature underlying it. A
balanced antioxidant defence in patients following primary pterygium
surgery is also important [30]. 8-OHdG is a ubiquitous marker of
oxidative stress with a high mutagenic potential. It is a sensitive and
stable biomarker for DNA damage estimation and has been expressed
more in the epithelium of the head of primary pterygium compared to
the healthy conjunctiva. While pterygium is considered to be a non-
metastatic lesion with limited local invasion, the presence of 8-OHdG
could conﬁrm a visible genetic instability which is in contrast to its
benign clinical course [6,31].
HIF-1α plays an important role in the modulation of cell metabolism
and survival pathways. A coordinated activation and increase of HIF-1α
and heat shock proteins in pterygium, may represent an adaptive
process for the survival of cells undergoing stressful conditions [32].
Pterygium epithelial cells seem to keep their potential to divide and
thus support the view of this disease being caused by altered limbal
stem cells, also being conﬁrmed by the presence of telomerase in
pterygium epithelium [11]. Although there have been reports on the
presence of stem cell markers within the eye, to the best of the authors’
knowledge, there has been no evidence for their presence in pterygium.
Sox2 has been described as being expressed in many epithelial cell
types, including conjunctival epithelial cells. In the conjunctival ocular
surface epithelial cells, but not ocular stromal cells, the pluripotent
stem cell marker Oct4 has been found expressed [33]. ABCG-2 has a
role in the maintenance of retinal stem cells under the regulation of
Fig. 6. Pterygium tissue and 3D outgrowing cells stained for epithelialcell markers. Pterygium tissue-containing cultures (A, C), and outgrowing cells forming 3D structures (B, D) were
stained for CK19 and CK8-18, respectively (Magniﬁcation: 40×). White bar represents data from pterygium tissue, while the black bar shows results from independently grown 3D
outgrowing cells. Data are expressed as mean ± SD.
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Notch signalling. The expression of ABCG-2 in canine limbal epithelial
cells has been considered a useful marker for presence of putative
corneal epithelial stem cells and proliferation [34,35]. The ex vivo 3D
tissue engineered pterygium outgrowths and the graft-containing
cultures expressed all of these stem cell markers (Sox2, Oct4 and
ABCG-2).
It is believed that the multifunctional molecules MUC1 and MUC4
are involved in the barrier function, protection and lubrication of the
ocular surface, signalling and that they are osmosensors. These proteins
can be expressed by both corneal and conjunctival epithelia [36,37],
while their expression in the pterygium graft-containing cultures and
the stratiﬁed outgrowing cells was clearly high, probably making the ex
vivo model for pterygium being close to a goblet cell hyperplasia as
well.
MMC has often been used to reduce recurrence of pterygium in
connection with conjunctival autografts, amniotic membrane trans-
plantation and radiation or chemotherapeutical agents’ treatment
[38,39]. MMC suppresses the proliferation of ﬁbroblasts by inhibiting
DNA synthesis, hence it can also aﬀect normal tissues and cause
complications such as scleral necrosis, corneal perforation, corneal
oedema, secondary glaucoma, corneal calciﬁcation and cataracts, thus
it must be used with caution [1]. In this study, MMC reduced the level
of secreted cytokines (in particular IL-6), which provides a combined
anti-inﬂammatory and anti-proliferative therapy for pterygium at a
Fig. 7. Pterygium tissue and 3D outgrowing cells stained for secretory markers. Pterygium tissue-containing cultures (A, C), and outgrowing cells forming 3D structures (B, D) were
stained for MUC1 and MUC4, respectively (Magniﬁcation: 40×). White bar represents data from pterygium tissue, while the black bar shows results from independently grown 3D
outgrowing cells. Data are expressed as mean ± SD.
Table 2
Expression of a wide range of markers expressed in pterygium grafts obtained directly
from surgery and compared to long-term cultivated 3D outgrowths from pterygium




Pluripotency markers Vim 26.5 ± 3.5% 43.7 ± 4%
ΔNp63 13.9 ± 0.9% 12.3 ± 1.5%
Stemness markers Sox2 22.2 ± 0.9% 15.3 ± 0.6%
Oct4 34.2 ± 1.6% 39.2 ± 2.5%
ABCG-2 25 ± 5% 32.7 ± 6.6%
Oxidative stress and
hypoxia markers
OHdG 42.4 ± 3% 62.3 ± 8.6%




CXCR4 27.2 ± 4.5% 67.3 ± 4.7%
Ki-67 5.1 ± 0.4% 1.2 ± 0.3%
Epithelial cell markers CK19 0% 11.9 ± 3.7%
CK8-18 24.3 ± 6.5% 0%
Secretory markers MUC1 13.1 ± 4.3% 63.7 ± 5.7%
MUC4 32.2 ± 3.3% 55.3 ± 5%
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cellular and molecular level.
The pterygium outgrowing cells were still viable after having
undergone more than three months cultivation time, which was further
conﬁrmed by the high level expression of CD47. The surface marker
proﬁle of ex vivo cultivated outgrowing cells showed that CD44, a
protein expressed actively on dividing cells [40], is moderately
expressed in the stratiﬁed outgrowing cells. The expression of ECM
attachment proteins, which is vital for the maintenance of cellular
growth within the pterygium, was low (CD146/MCAM, CD112/Nectin-
2) and moderate (CD166/ALCAM, CD44/H-CAM). Those markers could
also be found in LESCs, while the expression of CD73 and CD105 in 3D
outgrowing cells from pterygium was in general lower than that found
in LESCs [17]. Expression of CD105 has been described previously to
have a role in neovascular endothelial cells formation in the subepithe-
lial area of primary pterygia, while a correlation between the expres-
sion of VEGF in the stroma and CD105-MVD in primary pterygia has
also been proposed. Overexpression of VEGF and CD105-MVD can
contribute to pterygium progression by increasing angiogenesis and
growth [41]. Expression of the hematopoietic cell surface markers
CD34 and ‘don't eat me' signal CD47 in the 3D outgrowing cell from
pterygium cells was low and high, respectively. The population of 3D
outgrowing cells from pterygium contained a low level of the early
progenitor cell marker CD117/c-kit.
In conclusion, it has been demonstrated that human pterygium
explants can give rise to 3D outgrowing cells in a medium containing
FBS as the only growth supplement. The cells were viable, could
proliferate and migrate out of the grafts and form a stratiﬁed structure
very much like the one in vivo. The expanding cells carried proteins
related to an undiﬀerentiated state, but also a commitment towards
epithelial lineage. Stemness markers suggest a ﬂexible cell phenotype in
the long-term cultures. Manipulating the cell sheets was similar to
handling primary human tissues, presuming a possibility for use in
tissue engineering and drug discovery.
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